finch therapeutics is unlocking the therapeutic potential of the microbiome through our human-first discovery platform. we use machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. this human-centric discovery model leverages clinical data to focus our in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. this enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. our team values transparency, integrity, humility, and collaboration, and we intend to have fun while maximizing our ability to make an impact on patients’ lives.
Company profile
Ticker
FNCH
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Finch Therapeutics, Inc. • Finch Therapeutics Holdings, LLC • Finch Research and ...
IRS number
823433558
FNCH stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Apr 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Termination of a Material Definitive Agreement
7 Jul 23
8-K
Other Events
28 Jun 23
Latest ownership filings
4
JEFFERY A SMISEK
29 Mar 24
144
Notice of proposed sale of securities
28 Mar 24
SC 13G
Ugwumba Chidozie
13 Dec 23
4
JEFFERY A SMISEK
27 Nov 23
144
Notice of proposed sale of securities
22 Nov 23
4/A
Matthew P. Blischak
23 Jun 23
4
Matthew P. Blischak
9 Jun 23
4
Christian H. Lange
9 Jun 23
4
JEFFERY A SMISEK
9 Jun 23
4
Nicholas Haft
9 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.13 mm | 31.13 mm | 31.13 mm | 31.13 mm | 31.13 mm | 31.13 mm |
Cash burn (monthly) | 1.75 mm | 4.75 mm | 1.26 mm | 9.07 mm | 1.75 mm | 3.51 mm |
Cash used (since last report) | 12.84 mm | 34.87 mm | 9.26 mm | 66.63 mm | 12.89 mm | 25.76 mm |
Cash remaining | 18.29 mm | -3.75 mm | 21.87 mm | -35.51 mm | 18.24 mm | 5.36 mm |
Runway (months of cash) | 10.5 | -0.8 | 17.3 | -3.9 | 10.4 | 1.5 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 1 |
Closed positions | 16 |
Increased positions | 1 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 1.56 bn |
Total shares | 12.87 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Crestovo Investor | 12.64 mm | $210.48 mm |
Baupost | 67.30 k | $574.00 k |
Susquehanna International | 59.03 k | $503.51 mm |
Avenir Management | 55.45 k | $472.95 mm |
Vanguard | 32.68 k | $278.73 mm |
Ikarian Capital | 7.92 k | $67.53 mm |
Bleichroeder | 971.00 | $8.28 mm |
Tower Research Capital | 657.00 | $5.60 mm |
UBS UBS Group AG - Registered Shares | 543.00 | $4.63 mm |
BLK Blackrock | 341.00 | $2.91 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Jeffery A Smisek | Common Stock | Sell | Dispose S | Yes | No | 2.61 | 1,600 | 4.18 k | 6,512 |
28 Mar 24 | Jeffery A Smisek | Common Stock | Sell | Dispose S | No | No | 2.57 | 6,642 | 17.07 k | 0 |
22 Nov 23 | Jeffery A Smisek | Common Stock | Sell | Dispose S | No | No | 3.64 | 1,470 | 5.35 k | 6,642 |
9 Jun 23 | Matthew P. Blischak | Stock Option Common Stock | Grant | Acquire A | No | No | 0.271 | 962,899 | 260.95 k | 962,899 |
8 Jun 23 | Christian H. Lange | Stock Option Common Stock | Grant | Acquire A | No | No | 0.285 | 10,000 | 2.85 k | 10,000 |
8 Jun 23 | Matthew P. Blischak | Stock Option Common Stock | Grant | Acquire A | No | No | 0.285 | 962,899 | 274.43 k | 962,899 |
News
Finch Therapeutics Has Been Granted European Patent Number EP3664823 Titled "Composition For Use In Preventing Or Treating An Enterococcal Blood Stream Infection".
6 May 24
Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
24 Apr 24
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
17 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
17 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
12 Apr 24